Recursion Pharmaceuticals
RXRX
247 hedge funds and large institutions have $2.12B invested in Recursion Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 87 increasing their positions, 52 reducing their positions, and 20 closing their positions.
230% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 20
67% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 52
67% more capital inflows, than outflows
Capital inflows: $180M | Capital outflows: $107M
24% more funds holding
Funds holding: 199 → 247 (+48)
3.01% more ownership
Funds ownership: 99.19% → 102.19% (+3%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
27% less call options, than puts
Call options by funds: $15.6M | Put options by funds: $21.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$43.8M |
| 2 |
Nikko Asset Management Americas
New York
|
+$12.9M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$12.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$10.2M |
| 5 |
JP Morgan Chase
New York
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$20M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.9M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$8.94M |
| 5 |
Morgan Stanley
New York
|
-$6.82M |
RXRX Hedge Fund Activity: Q1 2024 in Review
247 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q1 2024, worth a combined $2.12B — up 4.2% from $2.04B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new RXRX positions and 20 closed out — a net gain of 46 holders — while 87 added to existing stakes and 52 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $43.8M. The largest seller was State Street, cutting an estimated $20M.
- 247 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q1 2024, up from 199 in Q4 2023.
- Funds reported $2.12B of Recursion Pharmaceuticals stock for Q1 2024, up 4.2% quarter-over-quarter.
- 66 funds opened new Recursion Pharmaceuticals positions in Q1 2024 and 20 closed out, a net change of +46 holders.
- The largest Recursion Pharmaceuticals buyer in Q1 2024 was ARK Investment Management, an estimated $43.8M added.
- The largest Recursion Pharmaceuticals seller in Q1 2024 was State Street, an estimated $20M sold.
Based on aggregated 13F filings for Q1 2024.